| Qiu, chunguang |
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis |
|
|
| Not yet recruiting | N/A | 325 | RoW | FFR and FFRCT | CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China | Coronary Stenosis | 10/21 | 03/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
| Cai |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
| Fang, Hong |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
| Han, Liping |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Yang, Guangyuan |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
